Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026)

Absci's (ABSI) quarterly Net Income towards Common Stockholders came in at -$29.6 million in Q1 2026, down 12.35% year-on-year from -$33.8 million in Q1 2025, and little changed quarter-over-quarter from -$29.6 million in Q4 2025.

Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Absci has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$29.6 million for Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$29.6 million, down 12.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$118.4 million (down 10.2% YoY), and the FY2025 annual result was -$115.2 million, down 11.71% from the prior year.
  • Net Income towards Common Stockholders came in at -$29.6 million for Q1 2026 at Absci, roughly flat from -$29.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$19.5 million in Q4 2022 to a low of -$41.7 million in Q2 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$27.4 million (2024), against an average of -$27.3 million.
  • Across the five-year window, Net Income towards Common Stockholders slumped 146.67% in 2022 and surged 40.61% in 2024, its largest moves.
  • Absci's Net Income towards Common Stockholders stood at -$19.5 million in 2022, then declined by 20.92% to -$23.5 million in 2023, then fell by 23.1% to -$29.0 million in 2024, then fell by 2.0% to -$29.6 million in 2025, then declined by 0.13% to -$29.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$29.6 million (Q1 2026), -$29.6 million (Q4 2025), and -$28.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Absci 1.13 Bn 1.01 Bn - -29.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.60 Mn
Dec 31, 2025 -29.56 Mn
Sep 30, 2025 -28.71 Mn
Jun 30, 2025 -30.57 Mn
Mar 31, 2025 -26.35 Mn
Dec 31, 2024 -28.98 Mn
Sep 30, 2024 -27.40 Mn
Jun 30, 2024 -24.75 Mn
Mar 31, 2024 -21.98 Mn
Dec 31, 2023 -23.55 Mn
Sep 30, 2023 -21.99 Mn
Jun 30, 2023 -41.67 Mn
Mar 31, 2023 -23.36 Mn
Dec 31, 2022 -19.47 Mn
Sep 30, 2022 -27.26 Mn
Jun 30, 2022 -28.68 Mn
Mar 31, 2022 -29.49 Mn
Dec 31, 2021 -25.17 Mn
Sep 30, 2021 -23.88 Mn
Jun 30, 2021 -42.25 Mn